FOXO Technologies

Modernizing the longevity insurance industry with molecular biotechnology

FOXO Technologies is transforming the global longevity insurance industry with a next-generation underwriting protocol and consumer engagement platform based on epigenetic technology and insights.FOXO Technologies Inc. uses AI-driven bioinformatics and microarray technologies to develop and commercialize epigenetic biomarkers of health and aging.

FOXO provides insurers, health researchers, and life science companies with laboratory services, microarray design, and AI-driven bioinformatics software solutions for generating novel health-based insights into lifespan.

Visit website: https://foxotechnologies.com/

foxo-bioscience

foxo_tech

Details last updated 24-Apr-2021

FOXO Technologies is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.

People at FOXO Technologies

Jon Sabes

Entrepreneur, founder and CEO of FOXO Technologies

Brian Chen

Chief Science Officer at FOXO Technologies.

FOXO Technologies News

FOXO licenses use of epigenetic clocks in life insurance industry

Longevity Technology - 05-May-2021

Modernizing life insurance to keep its customers healthy and alive

More Ageing Research information, news and resources

Topics mentioned on this page:

Epigenetics